Trial targeting tumours
Dr Gerard Goh with surgical screens
A new device that targets hard-to-kill tumours is the focus of a research trial led by The Alfred's interventional radiology team.
Hypervascular tumours are attached to a large number of blood vessels, and can be found anywhere in the body. Due to the increased risk of bleeding, they are often treated with a process called embolisation.
During embolisation, microscopic particles or a liquid, is injected into the tumour to cut off the blood flow so the tumour can no longer survive or grow.
While embolisation is not a new approach to treat hard-to-remove tumours, the Alfred team is the first to trial a new device designed to target them deeper, with the aim of destroying more cancer cells.
The Alfred’s head of Interventional Radiology Dr Gerard Goh said the new device, Embrace Hydrogel Embolic System (HES), has shown promising results from it’s in-human trial.
“We’re excited to be the first centre to enrol patients in this global, randomised trial," said Dr Goh.